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A b s t r a c t  
Nanolipid carriers (NLC) are developed as an alternative to solid lipid nanocarriers in order to 
increase the payload and to prevent drug expulsion. In this study, NLCs loaded with ciprofloxacin 
hydrochloride (CIP) and N-Acetyl cysteine (NAC) were prepared and evaluated for its delivery to the 
lung for treatment of the symptoms of cystic fibrosis and chronic obstructive pulmonary 
disorder.NLCs prepared by emulsification and sonication technique using cetyl palmitate (the solid 
lipid, 2%) and oleic acid (as the liquid lipid, 2%) and Tween80 (surfactant, 0.25%) showed smaller 
particle sizes (of199.1 ±1.859 nm) and relatively high encapsulation efficiencies (72.143±1.8 %.) and 
optimum zeta potential (-38.27 ± 0.384 mV).A novel DPI formulations loaded with the NLC 
containing CIP(CIP-DPI), NAC (NAC-DPI) and CIP/NAC combination (CIP-NAC-DPI) wereprepared 
by freeze drying method using Lactose (8%w/v) as a cryoprotectant. The DPI prepared showed 
good flow properties, prolonged drug release and improved stability.In-vitro drug release profile of 
CIP HCl in case of CIP-NLC showed 55 % release in 15 hours while it was 60% in case of CIP-NLC-
DPI formulation. Similar is the case with NAC formulations. Following intratracheal administration in 
rat model, the percentage of CIP extracted from lungs was 70.2% in case on CIP-NAC-DPI against 
49.8% for CIP-DPI and 42.1% for plain CIP. This amount is about 1.6 times increase in CIP in lungs 
by co-administration with NAC. However, no appreciable change in the residence time of CIP in 
lungs after intratracheal administration of CIP-DPI and combined DPI (CIP-NAC-DPI) was noted. 







Cystic fibrosis is an inherited chronic lung disease in which 
patients have mucus-clogged lungs that leave them vulnerable to 
repeated, ever more serious respiratory infections.Bacterial 
infections lead to biofilm formation and host inflammatory 
responses and the ultimate resistance to antibacterial therapies 
results in increased morbidity and mortality [1, 2]. This condition is 
difficult to treat by oral administration due to bio-availability 
problems to lungs and aerosol formulation containing antibiotic 
alone would be ineffective due to thick mucus which acts as 
barrier for penetration. These conditions warrants for the use of 
antibiotic combination with mucolytics by pulmonary delivery.  
Drug delivery to the lungs using dry powder inhalers (DPI) 
represents a potential delivery route for the treatment of several 
pulmonary disorders[3].This non-injective route has many 
advantages over other sites of administration because it has a 
rapid onset of action, fewer systemic side effects, high 
bioavailability, reducing frequent dosing, avoidance of the first-
pass metabolism, local action for pulmonary diseases, and 
convenience to patients when administered[4].However, for 
successful development of pulmonary drug delivery systems is a 
challenge in terms of inhalability, stability and size control [5]. 
Physicochemical characteristics of the formulation could influence 
aerodynamic size of the particles and ultimately affect the intrinsic 
tendency of aerosol particles to deposit in lungs, due to their 
shape, size and density.In several studies, size of the particles for 
deposition in the lungs was found to be in the 1–5 μm range.[6]. 
For an ideal pulmonary drug delivery system, drug carriers with 
average size in nanometer range such as liposome [7] 
nanoparticles [8], exhibit some well-defined and delicate 
characteristics, which are suited for pulmonary delivery of drugs 
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Nano lipid carriers (NLCs) are new generation nano particulate 
carrier system, developed in order to overcome the limitations of 
first generation lipid nanoparticles i.e. solid lipid nanoparticles 
(SLN).  In  NLC  the  oil  component  of  the  o/w  emulsion  is  
replaced  by a  blend  of  a  solid  lipid  and  an  oil  leading  to  a  
solid  particle  matrix at body temperature[9]. The NLCs 
agglomerates produced were found to have excellent inhalation 
properties and improved physicochemical properties.Bioadhesive 
properties of NLC  due  to  their  small  particle  size  as  well  as  
their  lipophilic  character  lead  to  longer  residence  time  in  the  
lung. 
Ciprofloxacin hydrochloride (CIP HCl), a member of the 
fluorinated quinolone family, has a wide coverage against both 
gram-positive and gram-negative organisms and has shown good 
potential as an inhaled medicine.[10]It is efficient for the treatment 
of clinical complications of cystic fibrosis. It has also been shown 
to demonstrate good in vitro bactericidal activities against a 
number of pathogens that cause respiratory infections.[11]. Oral 
and intravenous forms of ciprofloxacin though are used clinically 
to treat respiratory tract infections,they exhibit relatively 
unfavorable pharmacokinetics profile in the lower respiratory tract, 
including a relatively short elimination half-life (1.0 to 1.6 h) and a 
low area under the concentration-time curve of 43 to 113 mg 
h/liter[12]. Indeed, as a liposomal formulation, ciprofloxacin is 
currently in phase 2 safety and efficacy studies[13]. 
In the mucolytic arena, dornase alfa[14], denufosol tetrasodium 
[15], lancovutide[16], hypertonic saline[17], heparin [18] and N-
acetyl-cysteine[19, 20] have all found therapeutic efficacy. Inhaled 
N-acetyl-cysteine (NAC) is believed to cause an increase in the 
osmotic pressure of the fluid lining the mucosal surfaces. The 
hyper tonicity produced induces transcellular water migration, a 
reduction in mucous viscosity and increased clearance via the 
cilia transport mechanism. This increase in mucus removal is 
beneficial for patients suffering from cystic fibrosis and chronic 
bronchitis.[21]It alsobreaks disulfide bonds in mucus and liquefies 
that makes it useful in thinning the abnormally thick mucus in 
cystic and pulmonary fibrosis patients. NAC is known to enhance 
CF sputum penetration (Suk JS et al, 2011) and was reported to 
transfer promising synthetic nanoparticle genes effectively to 
lungs of CF patients [22]. In addition, NAC inhibited growth of both 
gram-negative and gram-positive bacteria. [23].Some studies 
have also shown that mucolytic agents may inhibit antibiotic 
activity when used in combination[24]. However, Heaf et al. 
(1983),[25] described how mesna (Mistabron®), a mucolytic 
agent, despite inhibiting pseudomonal growth, did not reduce the 
bactericidal activity of azlocillin (acylampicillin antibiotic). 
Furthermore, in a study by Roberts and Cole (1981), 1% NAC 
was shown to potentiate the anti-pseudomonal activity of 
carbenicillin in vitro.NAC was also reported to increase the 
therapeutic efficacy of CIP when used in combination for the 
treatment and eradication of biofilms formed on ureteral stent 
surfaces[26] and may be a useful therapeutic option in partial 
biliary obstruction.[27]. 
The administration of antibiotic and mucolytic in dry powder 
aerosol form is one of the proposed strategies that can be 
adopted to reduce doses and, consequently, to reduce the side 
effects.[28]   Because inhaled powders work locally in the lung as 
a common site of action, lower doses are needed to achieve the 
same therapeutic effect as the oral doses.[29].There has been 
huge success in processing dry powder inhalers using a range of 
drug substances, including nifedipine, tacrolimus, and 
budesonide.[30] To the best of our knowledge, this is the only 
study demonstrating the use of CIP-NLC and NAC-NLC as DPI.  
Therefore, the aim of the present investigation is to prepare and 
evaluate stable DPI loaded with CIP-NLC and NAC-NLC for high 
pulmonary deposition, thereby enhanced accumulation in deeper 
parts of bronchi. 
Material and Method 
Material 
Ciprofloxacin hydrochloride (CIP HCl) was obtained from Innova 
Captab, Baddi and N-Acetyl cysteine(NAC) by Crescent 
Therapeutic limited, Baddi ( Himachal Pradesh , India) Cetyl 
palmitate and Oleic acid, Lactose, orthophosphoric acid, 
Trehalose, sucrose, mannitol, boric acid, Disodium hydrogen 
phosphate, potassium dihydrogen phosphate by Central Drug 
House, New Delhi, Tween 80 act as emulsifier was provided by 
Hi-Media Lab Pvt Ltd, Mumbai (India), 4- Chloro- 7 nitro-2, 1, 3-
benzoxadiazole from Sigma Aldrich, (U.S.A.), dialysis tubing, 
Sephadex-G-50 from Sigma Chemical co.( U.S.A.), Ethanol, 
Methanol, Hydrochloric acid by Renkem Chemicals, New Delhi 
(India) 
Methods 
Nano lipid carrier loaded with CIP HCl and NAC were prepared by 
emulsification and ultrasonication method reported previously[31]. 
Briefly, Drug was grinded along with surfactant and was added 
with the molten mixture of solid and liquid lipid at 40o C. 
Surfactant solution in water heated to 80o C was added to the 
drug-lipid mixture and homogenized for 6 minutes at 400 rpm, 
maintaining the temperature at 80o C to obtain fine emulsion. The 
emulsion was sonicated for 3 minutes at 60 amplitude using probe 
sonicator. The resultant mixture was cooled up to 2 to 3o C in 
refrigerator to form NLCs. 
The NLC dispersion obtained was added with lactose (8% w/v)as 
a cryoprotectant, mixed and was filled in 30 ml vials partially 
capped and lyophilized. Lyophlization was performedby freezing 
the mixture at −40°C followed by lyophlization for 24 hours in a 
laboratory freeze-drier (VIRTIS) keeping vacuum at 50 to 60mTorr 
and condenser temperature -60ºC. The lyophilized product 
obtained in the form of dry mass was capped full in the chamber 
and preserved in freeze until its further use. 
Optimization of process parameter 
The properties of NLCs like particle size, shape, density, drug 
entrapment efficiency depends on formulation and operational 
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parameters like concentration of emulsifier, concentration of solid 
lipid, solid lipid: liquid lipid, concentration of drug, homogenization 
time, sonication time etc. Individual batches were designed, 
according to single factor variation, in order to screen optimal 
formulation.Particle size and Polydispersity index (PDI) were 
considered as response parameters for optimization. 
Characterization of NLCs 
Measurement of size and zeta potentials of NLC 
The mean particle size diameter, PDI and zeta potential were 
measured in solution directly after synthesis using Beckman 
coulter Delsa Nano C Particle analyzer model DLS 4 C (Table 
1&2). CIP-NLC and NAC-NLC (2 ml) were added to the quartz cell 
of the photon correlation spectroscope. Measurements were 
taken at 90° opposite the incident light source and mean droplet 
size was calculated from intensity.  
Determination of Percentage Entrapment Efficiency  
Entrapment efficiency was determined by minicolumn 
centrifugation method using sephadex® G 50 solution (10% w/v). 
NLCs were slowly charged on prepared column and centrifuged at 
400 rpm for 3 mins and then the same procedure was repeated by 
adding 100 µl of water. The free drug gets bound to the gel when 
NLC passed through the gel and were collected from first and 
second stage of centrifugation. The eluted NLC were heated at 
80◦C to rupture the NLC and centrifugation was done for 3 mins 
at 3000 rpm and liberated drug was estimated 
spectrophotometrically. 
Entrapment efficiency (%) = [Entrapped drug/Total drug]*100 
Solid state characterization of DPI 
Solid state characterization of DPI formulations like Angle of 
repose, Both Bulk density (BD) and tapped density (TD) 
determined by standard Pharmacopoeia procedures and were 
tabulatedin Table 3.The Compressibility Index of the powder 
blend was determined by Carr’s compressibility index. The 
formula for Carr’s Index is as shown below; 
Carr’s Index (%) = [(TD-BD) x 100] / TD 
Particle morphology  
Particle morphology of the DPI was performed by Scanning 
Electron Microscopy (SEM) for determining the surface 
morphology, size and shape of formulation and to observe the 
aggregation property of NLC with carrier particles.  
In Vitro Drug Release  
In vitrorelease was evaluated by using a dialysis bag diffusion 
technique under sink condition. The drug release from CIP-NLCs 
and NAC-NLCs was performed in Phosphate buffer saline (PBS) 
(pH 7.4) using dialysis diffusion bag. Both thesuspensions were 
placed individually in dialysis bags (MWCO 12000 Da, Sigma 
Aldrich) and the dialysis bags were subsequently placed in flasks 
containing 200 ml dissolution medium (PBS pH 7.4) and stirred at 
150 rpm in a 37◦C in the incubator shaker. Aliquots of the 
dissolution medium were withdrawn at each time interval and the 
same volume of fresh dissolution medium was added to the flask 
to maintain a constant volume. Drug concentration in the 
dissolution medium was determined using UV/Vis 
Spectrophotometry (Shimadzu 1700) at 278 nm for CIP HCl and 
at 410 nm for NAC. All experiments were carried out in triplicates. 
The release profile were fitted to kinetic equations (zero order, 
first order, Higuchi release and Korsmeyer-peppas release, 
Hixson Crowell) to understand the release mechanisms.   
In vivo studies 
The developed lyophilized powders were studied in vivofor lung 
distribution on adult albino rats (wistar origin) of either sex 
weighing 150 ± 20 g. the animals were housed in animal house of 
I.S.F. College of pharmacy with free access to pelletized chow 
and water. The temperature was maintained at approximately 
26°C to 28°C. Animal experiments were approved by CPCSEA. In 
vivo studies of the selected formulations were performed after 
intra-tracheal administration with the help of a suitable delivery 
device (cannula). 
Intratracheal Administration 
Intratracheal instillation was performed as reported bySheket al 
(1990) and Joshi and Misra (2003)[32, 33]. Briefly, three wistar 
rats (180-220 g) were used in each group for each time interval. 
Rats were housed in individual plastic cages at a constant 
temperature. Animals were fasted overnight prior to each 
experiment. Rats were selected randomly and anaesthetized by 
intraperitoneal administration of ketamine (80 mg/kg). The trachea 
was exposed by blunt dissection of the sternohyoideus muscle 
and a small midline incision was made over the trachea between 
the fifth and sixth tracheal rings using a 20 gauge needle. The 
trachea was cannulated with PE200 tubing (5-7 cm) with the tip 
positioned approximately at the tracheal bifurcation. The PE50 
(10-15 cm) tubing connected to a glass Hamilton syringe (Waters, 
Bangalore, India) was inserted into the cannula and advanced to 
the bifurcation of the trachea. Solutions containing 100 µg plain 
CIP HCl[34] and NAC[35] or NLC encapsulated CIP HCl and NAC 
prepared by rehydration (30 min) of powder with 250 µL triple-
distilled water were instilled slowly over a 1 min period, followed 
by 50 µL normal saline. Animals that were to be killed at 1, 2, 4 
and 8h after administration had the cannula secured with sutures 
and the access cannula excised to leave a 1 cm protrusion. 
Animals were allowed to recover and, after recovery, animals 
were housed in individual plastic cages with free access only to 
water.  
Organ homogenate studies 
Animals exposed to various formulations were sacrificed after 1, 
2, 4, and 8 h and the lungtissue was removed, washed, dried 
using a tissue paper, weighed separately, and homogenized in 
phosphate buffer. The homogenized tissues (20%) were 
deproteinized with 100µl of acetonitrile and kept in dark for 30 min 
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and filtered. To the filtrate, 100µl of extraction fluid methanol was 
added with vigorous shaking and then centrifuged at 5000 rpm for 
30 minutes. The supernatant was separated and drug content 
was measured using UV- VIS Spectrophotometer. The amount of 
drug was calculated as percent drug recovery at different time 
intervals. 
Result and Discussion 
Optimization of process parameters 
Results of the optimization experiments with respect to particle 
size, PDI, Zeta potential and entrapment efficiency of CIP-NLCs 
by varying parameters like homogenization time, sonication time, 
and amount of solid lipid, liquid lipid and drug are tabulated 
inTable 1.Mean particle size as well as (PDI) werefound to be 
reduced with increasing homogenization (400 rpm) time up to 6 
mins,after which, particle size increased due to increase in kinetic 
energy of particle which lead to agglomeration. Similarly, the size 
of the NLCs decreased as the time of sonication increased from 1 
to 3min (Amplitude 60) and beyond this sonication failed to reduce 
the size. The phenomenon of excess energy input leading to an 
increase in droplet size of Nano Lipid Carrier by inducing re-
aggregation. The effects of Tween 80 concentration (0.1 % to 
0.25% w/v) was studied keeping lipid concentration constant(1% 
w/v). With increase in Tween-80 concentration up to 0.25 % (w/v), 
mean particle size dramatically reduced butno appreciable 
decrease was found with further increase in Tween-80 
concentration. On increasing the amount of solid lipid, size was 
found to be decreased. However, the mean particle size of lipid 
nanoparticles usually depends on various factors,e.g. type and 
concentration of lipids and surfactants, and on the viscosity of lipid 
phase. 
Concentration of liquid lipid showed much influence on size 
andentrapment efficiency (EE)of NLCs.  Liquid lipid due to less 
crystalline structure exhibit imperfection of lipid matrix and so 
offersmore space for incorporation of drug. On increasing the 
liquid lipid concentration, entrapment efficiency was first increased 
followed by marginal decrease. Increase in sizes was also shown 
by increasing the amount of drug payload andthe highest drug 
amount(20mg) showed acceptable size. Further increase in drug 
amountresulted in poor drug incorporation and larger particle size.  
The above optimized experimental parameters were also applied 
for the preparation of NAC NLC and the response parameter 
values of the batch prepared are given in Table 2. 
Particle morphology, size, zeta potential 
The size of the CIP loaded NLCs was found to be 199±5 nm and 
PDI was 0.196±0.94. In order to confirm the size of NLC and to 
observe surface morphological characteristics, TEM and SEM 
were carried out respectively. TEM (Figure 1) and SEM (Figure 2) 
photographs showed uniform size; mono-dispersed round shaped 
NLCs. Slight rough surface could be observed in majority of NLCs 
in SEM photographs. Zeta potential of NLVs estimated by 
electrophoretic mobility technique using zetameter was found to 
be -38.27mV indicating the stability of nanoparticle during storage. 
Entrapment efficiency 
Nanolipid carriers are capable to provide more room for 
accommodation of drug. Entrapment efficiency of CIP-NLCs was 
found to be 72.143% and that of NAC-NLCs was 68.14%. 
Entrapment was found to be increased with the addition of liquid 
lipid. In addition to the influence of liquid lipid, presence of 
surfactant (Tween 80) in the formula could have improved the 
loading capacity.  The presence of limited amount free drug (Not 
more than 20%) however, has advantage that it will contribute for 
initial raise in Cmax followed by steady state drug concentration 
due to sustained release of entrapped drug.  
Solid state Characteristics 
Solid state characteristics like angle of repose, bulk and tapped 
density, compressibility are essential parameters that determine 
the delivery efficiency of DPI formulations. These characteristics 
determined for DPI formulations are given in Table 3. Angle of 
repose, an index of flow characteristics of the DPIs prepared were 
well below 30oensuring good flow. Bulk and tapped density values 
were very low in comparison to plain drug crystals showing the 
possibilities of good aerodynamic flow behavior. True density of 
CIP powder is 2.1g/cm3 and that of NAC powder is 1.48g/cm3. 
In vitro drug release 
In-vitro drug release profile of CIP HCl from various CIP-NLCs is 
given in Figure 3 along with their comparison with respective DPI 
formulation (CIP-NLC-DPI). Percentage of CIP HCl release from 
the NLCs after 8h and 15 h was 30% and about 55% 
respectively.The initial drug release (8h) is because the of burst 
effect that do not correspond to the real mechanism of the drug 
release from NLCs. It is due to immediate dissolution of drug 
particles adsorbedon the surface of NLCs. About 60% of drug was 
released from NLCs within the first 24 h and the 70% drug was 
released upto 48 hrs. Drug release followed Higuchi 
kinetics(Table 4) indicating the release predominantly by diffusion. 
Increased diffusional distance due to the formation of drug 
depletion zone at particle surface and presence on the 
surrounding lipid shell barrier might have slowed down the release 
rate resulting sustained drug release profile. 
The release profile of NACfrom NAC-NLCs and NAC-NLC-DPI is 
depicted in Figure 3. It showed a biphasic release profile with 25 
% release in first 4 hrs followed by sustained release ofabout 55%  
and 65% in 24 h and 48 h. Drug release followed Higuchi kinetics. 
In vivo studies 
Concentration of drug and percentage drug recovery in 
lung tissue 
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Lung tissue distribution and percentage recovery in lungs of CIP HCl and NAC following intra tracheal administration of their free  
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Table 2: Optimized formulation of NAC NLC 
Size(nm) PDI Zeta potential Entrapment efficiency (%) 
22.4nm±2.4 0.163±1.3 6.14±1.2 68.143±13 
 
 
Table 3:Solid State properties of DPI 




CIP-NLC- DPI 21.4 0.312 0.386 23.718 
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Linear correlation coefficient (R2) 
CIP HCl NLC CIP HCl NLC DPI NAC NLC NAC NLC DPI 
Zero order 0.881 0.8712 0.8943 0.8646 
First order 0.881 0.8712 0.8943 0.8646 
Higuchi model 0.9703 0.9691 0.9905 0.9736 
Peppas-Korsemeyer model 0.8885 0.906 0.9351 0.9741 




Table 5: Conc. obtained and % recovered of CIP HCl with respect to time in lung tissue when given through intratracheal 
administration from free and DPI form respectively. 
 
Time CIP HCl CIP-NLC-DPI CIP-NLC-DPI and NAC-NLC-DPI 
Concentration(µg/ml) % recovered Concentration(µg/ml) % recovered Concentration 
(µg/ml) 
% recovered 
1 21.05±2.98 42.1±3.0 24.5±1.48 49.8±2.5 35.1±1.98 70.2±1.0 
2 16.2±2.94 32.4±2.5 22.4±3.34 44.8±2.0 31.49±2.43 62.9±3.4 
4 9.49±2.93 18.98±1.6 19.03±3.39 38.06±1.0 25.46±1.11 50.9±2.8 




Table 6: Conc. obtained and % recovered of NAC with respect to time in lung tissue when given through intratracheal administration 
from free and DPI form respectively 
 
Time NAC NAC-NLC-DPI NAC-NLC-DPI and CIP-NLC-DPI 
Concentration(µg/ml) % recovered Concentration(µg/ml) % recovered Concentration(µg/ml
) 
% recovered 
1 33.6±2.09 47.14±3.0 46.8±1.48±2.98 65.6±2.5± 49.98±1.98 70±2.34 
2 26.13±3.91 36.36±2.5 39.12±3.34±4.57 54.8±2.0± 42.84±2.03 60±2.97 
4 13.5±3.98 18.98±1.6 33.7±3.39±2.43 47.2±1.0± 39.2±1.45 54.98±3.05 










CIP HCl Plain CIP-NLC DPI CIP-NAC-DPI NAC-Plain NAC-NLC-DPI CIP-NAC-DPI 
1.6 9.3 6.8 1.5 7.7 7.9 
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Fig: 3In vitro drug release profilefrom a) CIP HCl NLC b) NAC NLC c) CIP HCl DPI d) NAC NLC DPI 
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Figure 4: Concentration of CIP HCl and NAC obtained with time from free and DPI form in lung tissue following intratracheal administration in 









Figure 6: Percentage of CIP (Left) and NAC (Right) recoveredin lungs with time following intratracheal administration of Plain (¨), Single drug 












































and DPI form are given in Table 5 & 6 respectively.  Drug 
retention and half-lifein lung tissue were calculated with the help 
of software kinetic.Lung uptake of the drug from the DPI was 
higher as compared to plain drug suspension. The % CIP HCl 
recovered at 1 h and 8h after intratracheal administration of CIP-
DPI was found to be 49.8 % and 29.4 % respectively. The values 
are 1.2 times at 1h and 12.8 times at 8 h when compared to free 
NLC. 
Residence time of CIP HCl and NAC in lung tissue was more in 
CIP-DPI and NAC-DPI than in the free form as shown in table7. 
Because in case of lyophilized NLC, clearance of the drug from 
the organ was less due to slow release of the drug from the NLC. 
CIP HCl and NAC longevity in lung tissue was a direct 
consequence of the retention of the Lipid nanoparticles at the site 
and the retention of the drugs in lipid nanoparticles. 
The potential for pulmonary delivery of CIP HCl and NAC may 
have clinical significance in the light of recent data demonstrating 
that CIP-NLC-DPI and NAC-NLC-DPI were highly effective, 
following intratracheal administration, in rat lungs. 
When the CIP HCl was given in combination with NAC DPI the 
percentage dose recovered in the lungs was found to be higher. 
The observation suggests that the mucolytic removes the 
physicochemical barrier i.e. mucus. Hence the concentration of 
antibiotic was higher in the lungs in case of combinational 
therapy. In case CIP HCl in combination with NAC DPI, the % 
dose recovered at 1h and 8 h after intratracheal administration 
was found to be 70.2% and 34.4% respectively. The values are 
1.6 and 17 times at 8h when compared to free CIP HCl plain. 
Conclusion 
In the present investigation, an attempt was made to enhance the 
bioavailability of CIP HCl in lungs by administering as its NLC and 
as the NLC loaded DPI in combination with NAC for efficient 
treatment of symptoms of Cystic fibrosis. The NLCs were 
prepared by emulsification and ultrasonication technique using 
Cetyl palmitate as solid lipid, oleic acid as liquid lipid   and 
Tween80 as surfactant. The in vitro release studies confirmed that 
in case of both the CIP-NLCs and NAC-NLCs the drug was 
released in a sustained manner. These types of release profiles of 
CIP-NLCs and NAC-NLCs resemble the drug enriched core 
model. In such a model, the drug enriched core is surrounded by 
a practically drug-free lipid shell. Due to the increased diffusional 
path and hindering effects by the surrounding solid lipid shell, the 
drug has a sustained release profile. The DPI formulation 
wasstable at refrigerated condition.Based on above results it was 
concluded that, nano lipid carriers are suitable carriers for 
incorporating CIP HCl and NAC. The effect of NLCs 
encapsulation on CIP HCl and NAC levels in lungs following 
administration was determined in rat model. NLC in DPI 
preparations offer several potential advantages such as higher 
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